Premium
IC‐04‐04: NEUROINFLAMMATION AND 18 F‐AV‐1451 PET FINDINGS IN SEMANTIC DEMENTIA
Author(s) -
Pascual Belen,
Zanotti-Fregonara Paolo,
Funk Quentin,
Pal Neha,
Rockers Elijah,
Yu Meixiang,
Roman Guatavo C.,
Schulz Paul E.,
Masdeu Joseph C.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2052
Subject(s) - temporal lobe , medicine , atrophy , cardiology , nuclear medicine , dementia , pathology , endocrinology , epilepsy , disease , psychiatry
memory. Finally, we performed gray matter masking and partial volume correction to examine group differences in mGluR5 binding when accounting for gray matter volume loss. Results:AD participants (73.165.1 years, CDR1⁄40.5-1.0) ranged from amnestic Mild Cognitive Impairment (n1⁄48) to mild dementia (n1⁄48). CN participants (71.568.4 years) were free of clinical disease (CDR1⁄40) (Table 1). AD participants – compared to CN participants – demonstrated significant reductions inmGluR5 binding (F(1,31)1⁄47.4, p1⁄40.011). Post hoc analyses revealed that mGluR5 binding in the hippocampus (p1⁄40.003), but not association cortex (p1⁄40.093) was reduced in AD (Table 2). Hippocampal reductions persisted after graymattermasking (p1⁄40.011) and partial volume correction (p1⁄40.050) (Table 3). Exploratory analyses revealed reductions in entorhinal cortex, and parahippocampal gyrus (Table 2, 3). Reduced hippocampal mGluR5 binding was associated with more severe disease (r 1⁄4 -0.534, p1⁄40.002) and lower episodic memory scores (r 1⁄4 0.398, p1⁄40.027) in the overall sample. Conclusions: [F]FPEB-PET revealed reductions in hippocampal mGluR5 binding in the early stages of AD. Further study is needed to refine the pattern ofmGluR5 reductions and the associations with cognitive and functional impairment. Quantification of mGluR5 binding in AD may expand our understanding of AD pathogenesis as well as the development of novel treatments and biomarkers.